(Total Views: 978)
Posted On: 05/07/2025 10:29:08 PM
Post# of 154602
Re: Bored Lawyer #152500
Quote:
What do we think about the low mOS? Is it still a focused on regulatory endpoint?
The low mOS was due to those on the 350mg dose. Hard to get good results when some of the patients are on a half useless dose of medication. 350mg was why Progenics gave up and shelved leronlimab.
The mOS for the 525mg/700mg dose was 12.1+ months. Hopefully they release how long the 525mg/700mg doses mOS actually is at the conference. With one year survival for all doses at 1 year being 41.3% I would expect the mOS for 525mg/700mg to be quite a bit higher than 12.1 months. Possibly 20% higher or more.
(15)
(0)
